Merck, Incyte immunotherapy combination effective in lung cancer study

(Reuters) - A combination of the Merck & Co immunotherapy Keytruda and a different type of drug that also helps the immune system fight cancer from Incyte Corp led to a high rate of durable responses in a small, ongoing study of patients with advanced lung cancer, according to data released on Wednesday.